Wyeth Seeks Approval To Launch 2 Drugs In Japan By 2007 End (Japan)
This article was originally published in PharmAsia News
Wyeth is seeking marketing approval to introduce two prescription drugs in Japan. The company will file a new drug application with the Japanese government for Tygacil and Viviant by the end of this year. Viviant is used for osteoporosis, while Tygacil is used to treat pneumonia and other infections. The new drug launches are part of Wyeth's aim to raise sales in Japan to $1 billion by 2010, nearly double that of 2006. (Click here for more - May Require Paid Subscription
You may also be interested in...
Deputy CEO Nicolas Hieronimus will take L’Oreal’s helm beginning in May 2021, with Jean-Paul Agon continuing as chairman, the firm announced on 14 October. The Estee Lauder Companies hires PepsiCo’s Gibu Thomas to lead its online business, and Coty appoints its first chief digital officer.
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.